Author

S. Yildiz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Organism:human· 1 Organism:zebrafish· 1

Frequent Co-Authors

A. Garcia-Sastre· 3 shared R. Rathnasinghe· 3 shared H. van Bakel· 2 shared L. Miorin· 2 shared M. Schotsaert· 2 shared S. Jangra· 2 shared T. Kehrer· 2 shared V. Simon· 2 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

A. Garcia-Sastre

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Impact of SARS-CoV-2 ORF6 and its variant polymorphisms on host responses and viral pathogenesis.

T. Kehrer, A. Cupic, C. Ye, S. Yildiz, M. Bouhhadou, N. A. Crossland, E. Barrall, P. Cohen, A. Tseng, T. Cagatay, R. Rathnasinghe, D. Flores, S. Jangra, F. Alam, N. Mena, , L. Miorin

This study shows SARS-CoV-2 ORF6 disrupts nucleo-cytoplasmic trafficking, inhibits IFN signaling, and modulates viral protein expression, with variant polymorphisms affecting its function.

bioRxiv · Oct 18, 2022Microbiology

Discovery of a SARS-CoV-2 Broadly-Acting Neutralizing Antibody with Activity against Omicron and Omicron + R346K Variants

J. A. Duty, T. A. Kraus, H. Zhou, Y. Zhang, N. Shaabani, S. Yildiz, N. Du, A. Singh, L. Miorin, D. Li, K. Stegman, S. I. Ophir, X. Cao, K. Atanasoff, R. Lim, , R. Allen

This paper identifies a broadly neutralizing antibody, STI-9167, effective against SARS-CoV-2 variants including Omicron and Omicron + R346K, and describes its development for clinical trials.

bioRxiv · Jan 19, 2022 · PreprintMicrobiology

Topoisomerase 1 inhibition therapy protects against SARS-CoV-2-induced inflammation and death in animal models.

J. S. Y. Ho, B. W.-Y. Mok, L. Campisi, T. Jordan, S. Yildiz, S. Parameswaran, J. A. Wayman, N. N. Gaudreault, D. A. Meekins, S. V. Indran, I. Morozov, J. D. Trujillo, Y. S. Fstkchyan, R. Rathnasinghe, Z. Zhu, , Jeya

This study shows that Top1 inhibition with Topotecan reduces SARS-CoV-2-induced inflammation and mortality in animal models.

bioRxiv · Dec 1, 2020 · PreprintMicrobiology